# US 2026/0152470 A1 · Small molecule inhibitors of bacterial toxins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0152470 A1
- Document ID: US20260152470A1
- Status: Published application
- Kind: A1
- Application number: 19/529,405
- Filed: 2026-02-04
- Published: 2026-06-04
- Earliest claimed: 2020-09-11
- Assignees: Artizan Biosciences
- Applicants: Artizan Biosciences, Inc.
- Inventors: William HOEKSTRA; Hyunji RYU; Priyanka CHINTHA
- Web page: https://patentgrep.com/patent/US20260152470A1

## CPC

- C07C 311/29: having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- C07C 323/41: Y being a hydrogen or an acyclic carbon atom
- C07D 209/08: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C07D 213/40: Acylated substituent nitrogen atom
- C07D 213/42: having hetero atoms attached to the substituent nitrogen atom (nitro radicals C07D213/26)
- C07D 213/71: to which a second hetero atom is attached
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 231/56: Benzopyrazoles; Hydrogenated benzopyrazoles
- C07D 277/28: Radicals substituted by nitrogen atoms
- C07D 333/20: by nitrogen atoms (nitro, nitroso radicals C07D333/12)
- C07D 333/34: Sulfur atoms
- C07D 333/36: Nitrogen atoms
- C07D 401/08: linked by a carbon chain containing alicyclic rings
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Described herein are compounds and compositions for use in treatment or prevention of an inflammatory bowel disease, gastrointestinal cancer, or a systemic bacterial infection in a subject in need thereof. The subject may be colonized by one or more pathogenic bacterial strains such as B. fragilis, E. faecalis, or C. perfringens. In certain aspects, the disclosure provides a method of diminishing the pathogenic effects of these bacterial strains by administering a compound that binds to and/or inhibits one or more toxins produced thereby.

## Claims

### Claim 1

A compound of Formula III:
or a pharmaceutically acceptable salt or stereoisomer thereof,
wherein:
X is —NH—;
Y is —OH;
R1 is —C1-C6 alkyl, —C1-C6 alkylene-OH, —(C1-C3 alkylene)-O—(C1-C3alkyl), —(C1-C3 alkylene)-S—(C1-C3alkyl), —(C1-C3 alkylene)-S—(C1-C3 haloalkyl), or phenyl, wherein the phenyl is optionally substituted with one or more groups selected from —OH, —OMe, halogen, —CHF2, —CH2F, and —CF3;
R2 is —(CH2)2-aryl or —(CH2)2-heteroaryl; and
R3 is H.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 is —C1-C6 alkyl, —(C1-C8 alkylene)-S—(C1-C8alkyl), or phenyl optionally substituted with one or more groups selected from —OH, —OMe, halogen, —CHF2, —CH2F, and —CF3.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R1 is methyl, ethyl, n-propyl, —(CH2)—SCH3, or

### Claim 4 (depends on 3)

The compound of claim 3, wherein R1 is ethyl.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R2 is —(CH2)2-phenyl or —(CH2)2-(5- to 14-membered heteroaryl).

### Claim 6 (depends on 1)

The compound of claim 1, wherein R2 is —(CH2)2-(5- to 14-membered heteroaryl).

### Claim 7 (depends on 1)

The compound of claim 1, wherein R2 is —(CH2)2-phenyl, —(CH2)2-pyridyl, —(CH2)2-indolyl, or —(CH2)2-thiophenyl.

### Claim 8 (depends on 1)

The compound of claim 1, wherein R2 is —(CH2)2-pyridyl.

### Claim 9 (depends on 2)

The compound of claim 2, wherein R2 is —(CH2)2-phenyl or —(CH2)2-(5- to 14-membered heteroaryl).

### Claim 10 (depends on 2)

The compound of claim 2, wherein R2 is —(CH2)2-(5- to 14-membered heteroaryl).

### Claim 11 (depends on 2)

The compound of claim 2, wherein R2 is —(CH2)2-phenyl, —(CH2)2-pyridyl, —(CH2)2-indolyl, or —(CH2)2-thiophenyl.

### Claim 12 (depends on 2)

The compound of claim 2, wherein R2 is —(CH2)2-pyridyl.

### Claim 13 (depends on 3)

The compound of claim 3, wherein R2 is —(CH2)2-phenyl, —(CH2)2-pyridyl, —(CH2)2-indolyl, or —(CH2)2-thiophenyl.

### Claim 14

A compound having the structure:
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 15 (depends on 14)

The compound of claim 14, wherein the compound is:
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 16 (depends on 14)

The compound of claim 14, wherein the compound is:
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 17 (depends on 14)

The compound of claim 14, wherein the compound is:
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 18 (depends on 14)

The compound of claim 14, wherein the compound is:
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 19 (depends on 14)

The compound of claim 14, wherein the compound is:
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 20 (depends on 14)

The compound of claim 14, wherein the compound is:
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 21 (depends on 14)

The compound of claim 14, wherein the compound is:
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 22 (depends on 14)

The compound of claim 14, wherein the compound is:
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 23 (depends on 14)

The compound of claim 14, wherein the compound is:
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 24 (depends on 14)

The compound of claim 14, wherein the compound is:
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 25 (depends on 14)

The compound of claim 14, wherein the compound is:
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 26 (depends on 14)

The compound of claim 14, wherein the compound is:
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 27 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers or excipients.

### Claim 28 (depends on 14)

A pharmaceutical composition comprising the compound of claim 14 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers or excipients.

### Claim 29 (depends on 1)

A method of treating an inflammatory bowel disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound of claim 1 or pharmaceutically acceptable salt thereof.

### Claim 30 (depends on 14)

A method of treating an inflammatory bowel disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound of claim 14 or pharmaceutically acceptable salt thereof.
